License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed
AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc.[i] for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancers. CMG901 is currently being evaluated in a Phase I trial for the treatment of Claudin 18.2-positive solid tumours, including gastric cancer. Preliminary results from the trial have